Disrupting normal circadian rhythms promotes tumor growth and suppresses the effects of a tumor-fighting drug, according to a new study publishing April 30 in the open-access journal PLOS Biology by Yool Lee, Amita Sehgal, and colleagues at the University of Pennsylvania. The results provide mechanistic support for "chronotherapy," the delivery of cancer drugs timed to the endogenous circadian rhythm.
* This article was originally published here
